Today's Top Biotech Stocks to Watch: Geron Corporation and Arena Pharmaceuticals

Today's top health care and biotech stocks.

Jun 12, 2014 at 8:26AM


Let's take a look at today's top stories in biotech and health care. Keep an eye out for Geron Corporation (NASDAQ:GERN) and Arena Pharmaceuticals (NASDAQ:ARNA)

Geron is soaring this morning on clinical update
Shares of clinical-stage biotech Geron are up over 30% in premarket this morning after the company announced that a partial clinical hold for its experimental myelofibrosis treatment called imetelstat has been lifted by the Food and Drug Administration. In March, the FDA placed a clinical hold on imetelstat after patients receiving the treatment exhibited signals for an increased risk of liver toxicity. Dr. Ayalew Tefferi of the Mayo Clinic has been providing additional safety data to the FDA since the hold was put into place, leading to today's partial release.

What's key to understand is that the FDA still has a clinical hold on imetelstat as a treatment for essential thrombocythemia and multiple myeloma. Moreover, Geron cannot initiate new clinical trials with the drug until the full hold is released.

I think today's news is a step in the right direction, but it remains to be seen if the FDA will release the hold for these other indications. It's also important to understand that the required laboratory studies will take some time to complete, so you shouldn't expect the full hold to be lifted anytime soon. As such, investors with a long term outlook might want to stay on the sidelines for the time being, especially since the bulk of Geron's value is directly tied to imetelstat.      

Arena could be in for a big day
Shares of anti-obesity pill maker Arena Pharmaceuticals gained over 4% in after hours trading yesterday following an interview with CEO Jack Lief on CNBC. Investors are apparently intrigued by his comments about a recent uptick in Belviq prescriptions, as well as his lack of commentary regarding a possible buyout by marketing partner Eisai. Adding fuel to the fire, Orexigen's competing drug Contrave had its regulatory review extended by three months yesterday, giving Belviq at least another quarter before it will face increased competition. 

While improving Belviq sales and a regulatory delay for a competing drug are good fundamental reasons to dig deeper in this mid-cap biotech, I think the buyout rumor simply doesn't have legs for a couple of reasons. We've heard this same rumor multiple times since Belviq's approval, and it has never panned out. And Belviq's sales as a treatment for chronic obesity have been lackluster, giving Eisai (in my opinion) little reason to make an offer. In sum, you should focus on Arena's underlying business -- and not potential buyout rumors -- when considering an investment. 

Leaked: A huge small-cap opportunity
This smart device –kept secret until now – could mark a new revolution in smart tech (with big implications for health care). It’s a gigantic market opportunity -- ABI Research predicts 485 million of its type will be sold per year. To learn about the small-cap stock making this device possible – the stock that could mint millionaires left and right when its full market potential is realized – click here.

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers